AstraZeneca has raised its revenue guidance for the full year after strong sales of its Evusheld Covid-19 antibody treatment and drugs to treat cancer and rare diseases.
在Evusheld新冠抗体治疗剂和治疗癌症和罕见疾病的药物销售强劲后，阿斯利康上调了全年营收指引。
您已阅读7%（218字），剩余93%（3107字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。